BRISTOL MYERS SQUIBB CO

Transcription

1 BRISTOL MYERS SQUIBB CO FORM 8-K (Current report filing) Filed 04/10/15 for the Period Ending 04/08/15 Address 345 PARK AVE NEW YORK, NY Telephone CIK Symbol BMY SIC Code Pharmaceutical Preparations Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/31 Copyright 2015, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use.

2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): April 10, 2015 (April 8, 2015) BRISTOL-MYERS SQUIBB COMPANY (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification Number) 345 Park Avenue New York, NY, (Address of Principal Executive Office) Registrant s telephone number, including area code: (212) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR ) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR e-4(c))

3 Item Other Events. On April 8, 2015, Bristol-Myers Squibb Company (the Company ) announced that it had completed the previously announced planned acquisition of Flexus Biosciences, Inc. A copy of the press release is filed as Exhibit 99.1 to this report and is incorporated herein by reference. Item Financial Statements and Exhibits. (d) Exhibits Press release of Bristol-Myers Squibb Company dated April 8, 2015.

4 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRISTOL-MYERS SQUIBB COMPANY Dated: April 10, 2015 By: /s/ Sandra Leung Name: Sandra Leung Title: General Counsel and Corporate Secretary

5 EXHIBIT INDEX Exhibit No. Description 99.1 Press release of Bristol-Myers Squibb Company dated April 8, 2015.

6 Exhibit 99.1 Bristol-Myers Squibb Completes Previously Announced Acquisition of Flexus Biosciences, Inc. (NEW YORK, April 8, 2015) - Bristol-Myers Squibb Company (NYSE: BMY) today announced that it has completed the previously announced planned acquisition of Flexus Biosciences, Inc. The transaction includes full rights to F001287, Flexus lead preclinical, small-molecule IDO1-inhibitor targeted for IND filing in the second half of 2015 and an IDO/TDO discovery program that includes its IDO-selective, IDO/TDO dual and TDO-selective compound libraries. A newly formed entity established by the current shareholders of Flexus will retain, from and after the closing, all non-ido/tdo assets of Flexus including those related to Flexus Phase 1 FLT3 and CDK4/6 inhibitor, its earlier stage small-molecule Treg cancer immunotherapy programs, and its current personnel and facilities. About Bristol-Myers Squibb Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit or follow us on Twitter at Bristol-Myers Squibb Forward-Looking Statement This press release contains forward-looking statements relating to the acquisition of Flexus by Bristol-Myers Squibb and the discovery, development and commercialization of certain investigational compounds. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the expected benefits of the acquisition will be realized. In addition, the compounds described in this release are subject to all the risks inherent in the drug development process, and there can be no assurance that the development of these compounds will be successful. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb s business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb s Annual Report on Form 10-K for the year ended December 31, 2014, its Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

7 Contacts Bristol-Myers Squibb Media: Ken Dominski, , Sarah Koenig, , Investors: Ranya Dajani, , Flexus Media and Investors Yujiro Hata, Flexus Chief Operating Officer, ,